prior-art
39 cases — ← All topics
| Case | Title | Lower Court | Docketed | Status | Flags | Tags | Question Presented |
|---|---|---|---|---|---|---|---|
| 25A884 | CPC Patent Technologies PTY Ltd. v. Apple Inc. | Federal Circuit | 2026-02-05 | Application | federal-circuit patent-appeal patent-validity prior-art rule-36 unpatentability | Question not identified. | |
| 25-570 | Agilent Technologies, Inc. v. Synthego Corp. | Federal Circuit | 2025-11-13 | Pending | Response RequestedResponse Waived | anticipation burden-of-proof enablement patent-validity printed-publications prior-art | 1. Should printed publications be presumed to be enabling when a party challenging the validity of issued patent claims asserts that a printed publ… |
| 25-308 | Lynk Labs, Inc. v. Samsung Electronics Co., Ltd., et al. | Federal Circuit | 2025-09-16 | Pending | Amici (5)Response RequestedResponse Waived | inter-partes-review patent-act patent-applications printed-publications prior-art statutory-interpretation | Whether patent applications that became publicly accessible only after the challenged patent's critical date are "prior art * * * printed publicatio… |
| 25A233 | Agilent Technologies, Inc. v. Synthego Corp. | Federal Circuit | 2025-08-28 | Presumed Complete | biotechnology crispr federal-circuit patent-enablement prior-art research-and-development | Whether the Federal Circuit's presumption of enablement for prior art publications in unpredictable technological fields improperly undermines patent … | |
| 25A14 | Lynk Labs, Inc. v. Samsung Electronics Co., Ltd., et al. | Federal Circuit | 2025-07-03 | Presumed Complete | america-invents-act critical-date inter-partes-review patent-challenge printed-publication prior-art | Whether an abandoned patent application that was not publicly accessible before a patent's critical date can nonetheless qualify as 'prior art' under … | |
| 24-866 | Converter Manufacturing, LLC v. Tekni-Plex, Inc. | Federal Circuit | 2025-02-13 | Denied | administrative-law burden-of-proof patent-enablement patent-validity prior-art statutory-interpretation | Whether the patent challenger bears the burden of proving enablement of prior art under Sections 102 and 103 of the Patent Act | |
| 23-1349 | Provisur Technologies, Inc. v. Weber, Inc. | Federal Circuit | 2024-06-27 | Denied | Response Waived | confidentiality federal-circuit inter-partes-review on-sale-bar patent-law patent-law-35-usc-311-b printed-publication prior-art public-accessibility | Did the Federal Circuit err in holding that a product manual distributed with an on-sale product constitutes a printed publication that can be asserte… |
| 23-1052 | Seirus Innovative Accessories, Inc. v. Columbia Sportswear North America, Inc. | Federal Circuit | 2024-03-25 | Denied | Response Waived | comparison-prior-art design-patent function functional-limitations infringement ornamental ornamental-design patent-infringement prior-art same-article | Whether function must be disregarded in defining the scope of comparison prior art relevant to design patent infringement |
| 23-739 | Jodi A. Schwendimann, fka Jodi A. Dalvey v. Neenah, Inc., et al. | Federal Circuit | 2024-01-09 | Denied | 35-usc-103 federal-circuit-review ksr-standard ksr-v-teleflex obviousness patent-law primary-reference prior-art wbip-v-kohler yeda-v-mylan | Obviousness analysis under 35 U.S.C. § 103 | |
| 23-575 | Fleur Tehrani v. Hamilton Technologies LLC | Federal Circuit | 2023-11-28 | Denied | 35-usc-103 federal-circuit obviousness patent patent-invalidation patent-law posita prior-art | Whether the Court of Appeals for the Federal Circuit erred in its analysis | |
| 23A344 | Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., et al. | Federal Circuit | 2023-10-17 | Presumed Complete | KSR-standard obviousness patent-law pharmaceutical-patents predictable-result prior-art | Whether the Federal Circuit's obviousness analysis complies with the Supreme Court's standard in KSR International Co. v. Teleflex Inc. by requiring t… | |
| 22-1066 | CareDx Inc., et al. v. Natera, Inc., et al. | Federal Circuit | 2023-05-03 | Denied | Amici (1)Response RequestedResponse WaivedRelisted (2) | 35-usc-101 medical-diagnostics method-patent natural-phenomenon patent-eligibility patent-infringement prior-art scientific-innovation section-101 statutory-interpretation | Whether a new and useful method for measuring a natural phenomenon that improves upon prior methods for measuring that very same phenomenon is eligibl… |
| 22-927 | Nike, Inc. v. Adidas AG, et al. | Federal Circuit | 2023-03-23 | Denied | Response RequestedResponse WaivedRelisted (2) | 35-usc-316 america-invents-act claim-construction inter-partes-review patent-holder patent-law patent-trial-and-appeal-board prior-art substitute-claims | Whether, in inter partes review, the Patent Trial and Appeal Board may raise sua sponte a new ground of prior art that the petitioner neither cited no… |
| 22-544 | Innovation Sciences, LLC v. Amazon.com, Inc., et al. | Federal Circuit | 2022-12-14 | Denied | Response Waived | 35-usc-102 anticipation anticipatory-reference clear-and-convincing clear-and-convincing-evidence invention patent patent-infringement patent-invalidity prior-art | Whether an inference that a device that could have existed before the invention thereof by an inventor is properly treated as an anticipatory referenc… |
| 22-26 | Larry G. Junker v. Medical Components, Inc., et al. | Federal Circuit | 2022-07-08 | Denied | Response Waived | commercial-offer contract-law federal-circuit on-sale-bar patent-infringement patent-invalidation prior-art standing third-party-quotation | May a price quotation invoke the on-sale bar when made by a third party who had no right to sell the invention and with no involvement by the patentee… |
| 21-1106 | Thaddeus Gabara v. Facebook, Inc. | Federal Circuit | 2022-02-10 | Denied | Response Waived | 35-usc-101 abstract-idea data-structure patent-claims patent-eligibility preemption prior-art section-101 two-step-framework | What is the appropriate standard for determining whether a patent claim is 'directed to' a patent-ineligible concept under step 1 of the Court's two-s… |
| 21-893 | Apotex Inc., et al. v. Cephalon, Inc., et al. | Federal Circuit | 2021-12-16 | Denied | 35-usc-103 drug-reformulation inventive-process ksr-v-teleflex motivation motivation-to-combine obviousness obviousness-standard patent patent-law person-of-ordinary-skill prior-art | Whether claimed inventions involving reformulating and administering an old drug in ways that are no better than prior techniques, and which had been … | |
| 21-819 | Baxter Corporation Englewood v. Becton, Dickinson and Company | Federal Circuit | 2021-12-02 | Denied | Amici (1)Response RequestedResponse WaivedRelisted (2) | administrative-procedure administrative-procedure-act expert-testimony inter-partes-review ordinary-remand-rule patent patent-challenge prior-art remand-rule statutory-interpretation | Whether the Federal Circuit's practice of allowing IPR petitioners to rely on evidence other than patents and printed publications to fill in gaps in … |
| 21-193 | Centripetal Networks, Inc. v. Cisco Systems, Inc. | Federal Circuit | 2021-08-11 | Denied | Response Waived | accessibility patent patent-publication patent-statute printed-publication prior-art public-accessibility software software-disclosure trade-secret | Can a document qualify as a printed publication if it is stored on a password-protected website, not accessible to the public, and available only to c… |
| 20-1604 | Biogen MA Inc. v. EMD Serono, Inc., et al. | Federal Circuit | 2021-05-18 | Denied | anticipation claim-construction incentives medical-treatment method-of-treatment novelty patent patent-law patent-validity prior-art recombinant-protein | Whether courts may disregard the express claim term 'recombinant' so as to render a method-of-treatment patent anticipated—and thus invalid—in light o… | |
| 20-1517 | Fast 101 Pty. Ltd. v. Citigroup Inc., et al. | Federal Circuit | 2021-04-30 | Denied | Response Waived | 12(b)(6)-dismissal alice-mayo-test claim-construction claim-language inventive-concept patent-eligibility prior-art subject-matter-eligibility | Whether a court must evaluate the differences between prior art and the alleged inventive concept to fully appreciate the claim language |
| 20-1291 | WPEM, LLC v. SOTI Inc. | Federal Circuit | 2021-03-17 | Denied | 35-usc-282 35-usc-285 clear-and-convincing-evidence district-court-discretion exceptional-case patent-law patent-validity prior-art | Does a patent's presumption of validity afforded by 35 U.S.C. §282 limit a district court's discretion to find a case exceptional under 35 U.S.C. §285… | |
| 20-1258 | Ono Pharmaceutical Co., Ltd., et al. v. Dana-Farber Cancer Institute, Inc. | Federal Circuit | 2021-03-11 | Denied | conception conception-standard federal-circuit-rule inventorship-correction joint-inventorship non-obviousness novelty patent-law prior-art | Whether the Federal Circuit erred in adopting a bright-line rule that the novelty and non-obviousness of an invention over alleged contributions that … | |
| 20-7267 | Kevin L. Martin v. Cathleen Capron, et al. | Seventh Circuit | 2021-03-01 | Dismissed | Response WaivedIFP | 35-usc-112 court-of-appeals enablement invention patent prior-art | Whether the court of appeals erred in finding that the claimed invention meets the enablement requirement of 35 U.S.C. § 112 |
| 20-737 | B/E Aerospace, Inc. v. C&D Zodiac, Inc. | Federal Circuit | 2020-11-27 | Denied | Response Waived | administrative-procedure america-invents-act inter-partes-review obviousness patent-challenge patent-validity printed-publications prior-art statutory-interpretation | Whether the Board has authority to consider unpatentability on a ground of obviousness that is not 'only on the basis of prior art consisting of paten… |
| 20-74 | Andrei Iancu, Under Secretary of Commerce for Intellectual Property and Director, United States Patent and Trademark Office v. Eugene H. Luoma, et al. | Federal Circuit | 2020-07-27 | GVR | Response WaivedRelisted (2) | administrative-law america-invents-act enablement intellectual-property judicial-review obviousness patent-eligibility patent-review patent-trial-and-appeal-board patent-validity prior-art written-description | Whether the Patent Trial and Appeal Board's application of the statutory requirements for patentability under 35 U.S.C. §§ 101, 102, 103, and 112 was … |
| 19-1464 | Christopher Primbas, et al. v. Andrei Iancu, Director, United States Patent and Trademark Office | Federal Circuit | 2020-07-07 | Denied | Response Waived | abstract-idea alice-v-cls-bank claim-construction inventive-concept parker-v-flook patent-eligibility patent-office patent-prosecution prior-art | Whether recitation in a patent claim of a combination of steps determined to be inventive over an idea is 'sufficient to ensure that the patent in pra… |
| 19-1017 | Solutran, Inc. v. Elavon, Inc., et al. | Federal Circuit | 2020-02-14 | Denied | Response Waived | alice-test alice-v-cls-bank bilski-v-kappos business-method-patent business-method-patents claim-construction patent-eligibility prior-art subject-matter-eligibility | Does Alice's step one require that the claims be viewed as a whole and that consideration be given to the claimed advance over the prior art? |
| 19-584 | Nuvo Pharmaceuticals (Ireland) Designated Activity Company, et al. v. Dr. Reddy's Laboratories Inc., et al. | Federal Circuit | 2019-11-04 | Denied | Response Waived | 35-usc-112 enablement federal-circuit innovation patent patent-law pharmaceutical pharmaceutical-composition prior-art written-description | Whether the Federal Circuit erred by holding that, whenever the prior art teaches away from a pharmaceutical composition, the written description of a… |
| 18-1289 | Allergan, Inc., et al. v. Teva Pharmaceuticals USA, Inc., et al. | Federal Circuit | 2019-04-10 | Denied | Response Waived | blocking-patent blocking-patent-doctrine commercial-success graham-v-john-deere long-felt-need objective-indicia objective-indicia-of-non-obviousness obviousness patent-law patent-law-doctrine-of-obviousness prior-art | Whether the Federal Circuit erred in holding that objective indicia of non-obviousness may be partially or entirely discounted where the development o… |
| 18-1280 | Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc., et al. | Federal Circuit | 2019-04-08 | Denied | Amici (5) | blocking-patent-doctrine blocking-patents burden-of-proof graham-v-john-deere nonobviousness objective-indicia obviousness patent patent-law patent-obviousness pharmaceutical-innovation prior-art | Whether objective indicia of nonobviousness may be partially or entirely discounted where the development of the invention was allegedly 'blocked' by … |
| 18-1072 | James J. Macor v. United States Patent and Trademark Office | Federal Circuit | 2019-02-15 | Denied | Response Waived | 35-usc-102 35-usc-103 administrative-law analogous-art obviousness obviousness-standard patent patent-examination patent-law prior-art statutory-interpretation | Whether the standard for determining if prior art is 'analogous' in making rejections under 35 U.S.C. § 103(a) as obvious, and whether a finding of no… |
| 18-823 | ZUP, LLC v. Nash Manufacturing, Inc. | Federal Circuit | 2018-12-28 | Denied | Amici (1)Response Waived | invention invention-evaluation legal-analysis long-felt-need non-obviousness obviousness obviousness-standard patent patent-invalidity patent-law prima-facie prior-art rebuttal secondary-considerations | Whether evidence of 'secondary considerations' is less important in rebutting prima facie evidence of obviousness |
| 18-770 | Webtrends, Inc. v. Andrei Iancu, Director, Patent and Trademark Office | Federal Circuit | 2018-12-18 | Denied | Response Waived | 35-usc-101 abstract-idea alice-test claim-rejection federal-court patent patent-claims prior-art standing uspto | Whether the USPTO or a Federal Court can declare 20 patent claims to be directed to an unpatentable abstract idea without carrying out the Alice two-p… |
| 18-692 | Mylan Pharmaceuticals Inc., et al. v. UCB, Inc., et al. | Federal Circuit | 2018-11-27 | Denied | Amici (3)Response Waived | 35-usc-103 double-patenting federal-circuit graham-factors graham-v-john-deere invention-disclosure lead-compound-test obviousness patent-eligibility patent-law patent-law-doctrine-of-double-patenting patent-validity prior-art | Whether a patentee may obtain a second patent on the same invention actually covered by a former patent to the same patentee |
| 18-468 | SSL Services, LLC v. Cisco Systems, Inc. | Federal Circuit | 2018-10-12 | Denied | Amici (1)Response Waived | 35-usc-325(d) administrative-law administrative-procedure estoppel inter-partes-review judicial-review patent-office patent-review patent-validity predictability prior-art statutory-interpretation | Whether courts may review an agency's ruling on the multiple-proceedings rule under 35 U.S.C. § 325(d) |
| 18-441 | Accord Healthcare, Inc., et al. v. UCB, Inc., et al. | Federal Circuit | 2018-10-09 | Denied | Amici (1)Response Waived | 35-usc-103 lead-compound obviousness patent patent-invalidation patent-law pharmaceutical pharmaceutical-compound prior-art | Whether the Federal Circuit erred in holding that a patent claim to an obvious modification of a prior art compound was not invalid as obvious under 3… |
| 18-190 | Queen's University at Kingston v. Samsung Electronics Co., Ltd., et al. | Federal Circuit | 2018-08-13 | Denied | Response Waived | administrative-procedure-act burden-of-proof due-process enablement inter-partes-review patent-invalidity prior-art | Does the Federal Circuit's requirement that patent owners negate enablement of prior art in the first instance invert the statutory burden of proving … |
| 18-109 | Ariosa Diagnostics, Inc. v. Illumina, Inc. | Federal Circuit | 2018-07-24 | Denied | CVSGAmici (3)Response WaivedRelisted (2) | 35-usc-102 35-usc-119 disclosure federal-circuit filing-date patent patent-application patent-law patent-prior-art prior-art priority subject-matter | Unclaimed disclosures in a published patent application and an earlier application it relies on for priority enter the public domain and thus become p… |